Advertisement


Bernard J. Escudier, MD, on RCC: Results From the IMmotion151 Trial

2018 ASCO Annual Meeting

Advertisement

Bernard J. Escudier, MD, of Gustave Roussy, discusses patient-reported outcomes for atezolizumab plus bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma (Abstract 4511).



Related Videos

Breast Cancer
Immunotherapy

Helena Margaret Earl, MBBS, PhD, on Early Breast Cancer: Results From the Persephone Trial

Helena Margaret Earl, MBBS, PhD, of the University of Cambridge, discusses phase III study findings on 6 vs 12 months of adjuvant trastuzumab in patients with HER2-positive early b...

Sarcoma

Gianni Bisogno, MD, on Rhabdomyosarcoma: Results From the European Paediatric Soft Tissue Sarcoma Study Group

Gianni Bisogno, MD, of the University Hospital of Padova, discusses study findings on maintenance low-dose chemotherapy in patients with high-risk rhabdomyosarcoma (Abstract LBA2)....

Breast Cancer

Rebecca A. Dent, MD, on Triple-Negative Breast Cancer: Results From the LOTUS Trial

Rebecca A. Dent, MD, of the National Cancer Centre Singapore, discusses phase II study findings on first-line ipatasertib plus paclitaxel for locally advanced/metastatic triple-neg...

Kidney Cancer

Arnaud Méjean, MD, PhD, on RCC: Results From the Carmena Trial

Arnaud Méjean, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses his study’s potentially practice-changing finding that nephrectomy is no longer the standard of care for...

Breast Cancer

Joseph A. Sparano, MD, on Breast Cancer: Results of the TAILORx Trial

Joseph A. Sparano, MD, of Montefiore Medical Center, discusses phase III study results on chemoendocrine treatment vs endocrine treatment alone in hormone receptor–positive, HER2-n...

Advertisement

Advertisement



;
Advertisement